Last Updated : July 27, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Descovy | Emtricitabine /tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete | ||
| Dificid | fidaxomicin | Clostridium difficile infection | N/A | Withdrawn | ||
| Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Do not reimburse | Active | ||
| Dovato | dolutegravir / lamivudine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Duaklir Genuair | Aclidinium bromide/formoterol fumarate dihydrate | Chronic obstructive pulmonary disease | List with clinical criteria and/or conditions | Complete | ||
| Duobrii | Halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Duodopa | Levodopa / carbidopa | Parkinson's disease | Do not list | Complete |
Last Updated : July 27, 2024